AFM24 + Atezolizumab 840 MG in 14 ML Injection
Phase 1/2Terminated 0 watching 0 views this week💤 Quiet
33
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Advanced Solid Tumor
Conditions
Advanced Solid Tumor
Trial Timeline
Nov 19, 2021 → Jun 11, 2025
NCT ID
NCT05109442About AFM24 + Atezolizumab 840 MG in 14 ML Injection
AFM24 + Atezolizumab 840 MG in 14 ML Injection is a phase 1/2 stage product being developed by Affimed for Advanced Solid Tumor. The current trial status is terminated. This product is registered under clinical trial identifier NCT05109442. Target conditions include Advanced Solid Tumor.
Hype Score Breakdown
Clinical
13
Activity
8
Company
2
Novelty
4
Community
3
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT05109442 | Phase 1/2 | Terminated |
Competing Products
20 competing products in Advanced Solid Tumor
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| AK-105 | Akeso | Phase 1 | 32 |
| EXS21546 | Biotrial | Phase 1/2 | 33 |
| SY-1365 (Part 1) + Carboplatin + Fulvestrant + SY-1365 (Cohort 2) + SY-1365 (Cohort 5) + SY-1365 (Part 2 Single Agent) | Syros Pharmaceuticals | Phase 1 | 25 |
| Necitumumab + Gemcitabine + Carboplatin | Eli Lilly | Phase 2 | 52 |
| Pemetrexed + Erlotinib + Pemetrexed + Erlotinib | Eli Lilly | Phase 2 | 52 |
| NBTXR3 | Nanobiotix | Phase 1/2 | 36 |
| pegfilgrastim + LY2523355 | Eli Lilly | Phase 1 | 33 |
| SON-1010 | Sonnet BioTherapeutics | Phase 1 | 28 |
| SON-1010 | Sonnet BioTherapeutics | Phase 1/2 | 36 |
| BT1718 | Bicycle Therapeutics | Phase 1/2 | 33 |
| Zentalis + Gemzar | Zentalis Pharmaceuticals | Phase 2 | 44 |
| IMC-18F1 | Eli Lilly | Phase 1 | 33 |
| Tadalafil + Gemcitabine | Eli Lilly | Phase 1 | 33 |
| OKI-179 | OnKure Therapeutics | Phase 1 | 25 |
| OKI-219 + Fulvestrant + Trastuzumab + Tucatinib + Atirmociclib + Ribociclib | OnKure Therapeutics | Phase 1 | 25 |
| LY3499446 + Abemaciclib + Cetuximab + Erlotinib + Docetaxel | Eli Lilly | Phase 1/2 | 41 |
| LY3434172 | Eli Lilly | Phase 1 | 33 |
| ACR-2316 | Acrivon Therapeutics | Phase 1 | 25 |
| BBP-398 | LianBio | Phase 1 | 25 |
| LY3200882 + Pembrolizumab | Eli Lilly | Phase 1/2 | 41 |